Dipeptidyl Peptidase-4 (DPP-4) Inhibitors & Inflammatory Bowel Disease

Details

Basic Details

Status

Ongoing

Last Updated

Monday, July 14, 2025

Original Posting Date

Monday, July 14, 2025

Health Outcome(s)

inflammatory bowel disease (IBD)

Purpose

Drug and Outcome Analysis

Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR

No

Analytic Code Link(s) (1)

Incidence of Inflammatory Bowel Disease Following Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Use in Patients with Type 2 Diabetes Mellitus: An Inverse Probability of Treatment Weighting Analysis

Result(s) (7)

Coding Trend Analyses: Biopsy Coding Trend Analyses: Colectomy, Colostomy, and Ileostomy Coding Trend Analyses: Crohn's Disease Coding Trend Analyses: Diverticulitis and Colitis Coding Trend Analyses: Endoscopy Coding Trend Analyses: Ulcerative Colitis Counts and Characteristics of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor or Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor Users with Type 2 Diabetes: A Descriptive Analysis

Related Publication(s) and/or Presentation(s) (1)

Presentation: Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Dependent Glucose Co-Transporter 2 Inhibitors in the FDA Sentinel System